40 cents per share post approval:
It could represent 20,000 USA patients that renew 50% of their scripts with BOT getting 200 profit per $750 unit sale.
Kaken just had 272,000 new patients last 12 months.
40 cents?
If the US gets 200,000 patients like the above more like $4.
3 times the population more like $12
More effective sales and marketting more like $$$$$$$$$$
40 cents is still massively priced in to be a flop.
Ann: Final Sofdra Labelling Discussions with FDA, page-249
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |